EUVIMED · CrossrefJournal
The Lancet HIV
ISSN 2352-3018 · Elsevier BV
Latest articles
Safety, pharmacokinetics, and antiviral activity of a combination of TMB-365 and TMB-380 in people living with HIV suppressed with antiretroviral therapy in the USA: a phase 1b/2a, open-label, dose-escalation study
Epidemiological trends of HIV among individuals aged 15–54 years in South Africa from 2004 to 2025: a population-based, longitudinal cohort study
Integrating long-acting injectable cabotegravir for HIV prevention into the Brazilian public health system (ImPrEP CAB Brasil): a hybrid type-2 implementation-effectiveness cohort study
Weight management in people with HIV
Antiretroviral therapy, adiposity, and cardiometabolic risk in people with HIV
HIV, obesity, and stigma: lessons for programmes, policy, and practice
When race predicts weight gain on ART, what does it mean?
HIV acquisitions, safety, and pharmacokinetics of lenacapavir for HIV pre-exposure prophylaxis in pregnant and lactating women (PURPOSE 1): a substudy of a phase 3, randomised controlled trial
Interventions to improve viral suppression and adherence to antiretroviral therapy among people living with HIV: a systematic review and network meta-analysis
National and regional analysis of HIV transmission dynamics in Morocco: a mathematical modelling study
The Lancet HIV Commission on ageing and HIV: a global perspective
Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial
Safety and efficacy of switching to bictegravir–lenacapavir versus continuing bictegravir–emtricitabine–tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
Harm reduction makes uneven progress in Tanzania
Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial
Guidance on the clinical management of HIV-1 persistent low-level viraemia on antiretroviral treatment: a scoping review and an international Delphi consensus
Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial
The caveats of short-cycle antiretroviral therapy in adolescents living with HIV
Global mental health disparities among transgender women and transfeminine people living with HIV: a systematic review and meta-analysis of 63 studies
Short-cycle 4-days-per-week maintenance two-drug therapy in people living with HIV (ANRS-177 DUETTO): a randomised, open-label, multicentre, non-inferiority trial
Targeted universalism for long-acting PrEP: an urgent need to avoid risk targeting and build population-level impact
Ending HIV requires research in and with South Africa
Russia's internet blackout affects HIV services
Consideration of brain health in ART interruption studies
Consideration of brain health in ART interruption studies – Authors' reply
HIV prevention must incorporate acute HIV infection screening
Human impact of cuts to global aid in South Africa
Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE
Metabolic syndrome and cardiovascular risk on INSTIs
Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis
EUVIMED